Repatha shown to consistently reduce CD events

New data from the Repatha (evolocumab) cardiovascular outcomes trial (FOURIER) show that Repatha consistently and safely reduced cardiovascular events in patients with established cardiovascular disease regardless of baseline low-density lipoprotein cholesterol (LDL-C) level below or above 70mg/dL, says the drug’s maker, US biotech giant Amgen (Nasdaq: AMGN).

A separate analysis also demonstrated that already-marketed Repatha reduced cardiovascular events in patients being treated with maximum-intensity statin therapy. These results were presented at the 2017 National Lipid Association Scientific Sessions.

“We now have additional evidence of the benefit of evolocumab in reducing cardiovascular event risk, even in patients starting with LDL-C levels below the most aggressive current guideline targets and in patients already on maximum-intensity statin therapy,” said Marc Sabatine, chairman of the TIMI Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women's Hospital, and Professor of Medicine, Harvard Medical School, Boston.